- Home
- HASI vs ZLAB Comparison
HASI vs ZLAB Comparison
Compare HASI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HASI
- ZLAB
- Stock Information
- Founded
- HASI 1981
- ZLAB 2013
- Country
- HASI United States
- ZLAB China
- Employees
- HASI N/A
- ZLAB N/A
- Industry
- HASI Real Estate Investment Trusts
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- HASI Real Estate
- ZLAB Health Care
- Exchange
- HASI Nasdaq
- ZLAB Nasdaq
- Market Cap
- HASI 3.6B
- ZLAB 3.2B
- IPO Year
- HASI 2013
- ZLAB 2017
- Fundamental
- Price
- HASI $27.71
- ZLAB $26.13
- Analyst Decision
- HASI Strong Buy
- ZLAB Buy
- Analyst Count
- HASI 6
- ZLAB 6
- Target Price
- HASI $38.67
- ZLAB $57.22
- AVG Volume (30 Days)
- HASI 1.2M
- ZLAB 755.8K
- Earning Date
- HASI 11-06-2025
- ZLAB 11-06-2025
- Dividend Yield
- HASI 6.06%
- ZLAB N/A
- EPS Growth
- HASI N/A
- ZLAB N/A
- EPS
- HASI 1.59
- ZLAB N/A
- Revenue
- HASI $92,418,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- HASI $184.74
- ZLAB $41.80
- Revenue Next Year
- HASI $13.79
- ZLAB $49.93
- P/E Ratio
- HASI $17.45
- ZLAB N/A
- Revenue Growth
- HASI N/A
- ZLAB 32.56
- 52 Week Low
- HASI $21.98
- ZLAB $23.82
- 52 Week High
- HASI $36.56
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- HASI 38.10
- ZLAB 33.43
- Support Level
- HASI $27.72
- ZLAB $25.13
- Resistance Level
- HASI $29.10
- ZLAB $26.48
- Average True Range (ATR)
- HASI 0.80
- ZLAB 1.02
- MACD
- HASI -0.24
- ZLAB -0.30
- Stochastic Oscillator
- HASI 10.43
- ZLAB 19.80
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.